Sumitomo Pharma advances Asian business split with Marubeni

Sumitomo Pharma (TSE:4506) is progressing with its plan to separate its Asian business and form a strategic partnership with Marubeni Global Pharma Corporation. As announced on May 28, 2025, Sumitomo Pharma will transfer its Asian operations—currently managed through subsidiaries Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd.—into a newly established entity named SMP Jumbi Kabushikigaisya. This entity, with headquarters in Chuo-ku, Tokyo, was officially established on May 13, 2025, with capital of JPY 25 million. Founding Director Shigeyuki Nishinaka will lead the new company, whose business will focus on manufacturing and sales of pharmaceuticals. Following the absorption-type company split, 60% of SMP Jumbi Kabushikigaisya's shares will be transferred to Marubeni Global Pharma, with Sumitomo Pharma retaining the option to transfer the remaining 40% at a later date. The new company will become a consolidated subsidiary of Sumitomo Pharma and is considered a related party.